ZNTL · Zentalis Pharmaceuticals, Inc.
$5.11
+0.54 (+11.82%)
At close · Jul 17
Market Cap
$363.76M
Shares
71,186,348
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.11
Open$4.68
Day$4.68–5.34
52W$1.21–6.95
Avg vol 30d1.2M
Short int5.9M · 8.2% float · 3.2d
Short vol77%
Last earningsFeb 27, 2024
DataApr 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+84%
above
Price vs 50-day avg
+24%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
68%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+41%
trailing
6-month return
+74%
trailing
YTD return
+279%
this year
Relative strength
+66%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
2 of 101 funds reported for Jun 30 · net +19.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.24% of float · ▲ +17.8% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
101 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-125.2M
Balance sheet
$36.0M
net cash
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+84%
Bullish
Price vs 50-day avg
+24%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
68%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
2 of 101 funds reported for Jun 30 · net +19.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.24% of float · ▲ +17.8% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
101 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $5 · 68%
52-wk high $7
vs 200-day avg +84%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZNTL
this stock
Zentalis Pharmaceuticals, Inc.
|
$363.76M | +278.5% | -100.0% | — | 8.2% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZNTL | +4.7% | +41.2% | +73.8% | +5.4% | +278.5% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | +6.3% | +40.9% | +66.0% | +5.8% | +269.5% |